Everolimus - SoVarGen
Alternative Names: SVG 101Latest Information Update: 18 Sep 2023
At a glance
- Originator SoVarGen
- Class Anti-infectives; Anti-ischaemics; Antiepileptic drugs; Antineoplastics; Macrolides; Nootropics; Polyenes; Urologics; Vascular disorder therapies
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Partial epilepsies
Highest Development Phases
- Phase I Partial epilepsies
Most Recent Events
- 09 Aug 2023 Chemical structure information added
- 24 Jul 2023 Everolimus - SoVarGen is available for licensing as of 24 Jul 2023. http://www.sovargen.com/rd#section1